1. Prognostic impact of interhospital variation in adjuvant chemotherapy for patients with Stage II/III colorectal cancer: a nationwide study
- Author
-
Keiichi Arakawa, Kenichi Sugihara, H. Nozawa, Keisuke Hata, Tsutomu Tanaka, and Kazushige Kawai
- Subjects
Adult ,Male ,Oncology ,medicine.medical_specialty ,Colorectal cancer ,Adjuvant chemotherapy ,medicine.medical_treatment ,Antineoplastic Agents ,Disease ,Stage ii ,Young Adult ,03 medical and health sciences ,0302 clinical medicine ,Japan ,Internal medicine ,medicine ,Humans ,In patient ,Stage (cooking) ,Aged ,Neoplasm Staging ,Retrospective Studies ,Aged, 80 and over ,Chemotherapy ,business.industry ,Gastroenterology ,Retrospective cohort study ,Middle Aged ,Prognosis ,medicine.disease ,Hospitals ,Survival Rate ,Chemotherapy, Adjuvant ,030220 oncology & carcinogenesis ,Female ,030211 gastroenterology & hepatology ,Colorectal Neoplasms ,business - Abstract
AIM Clinical guidelines recommend adjuvant chemotherapy for high-risk patients with Stage II-III colorectal cancer. However, chemotherapeutic administration rates differ significantly between hospitals. We assessed the prognostic benefit of adjuvant chemotherapy in patients with Stage IIb/c colorectal cancer, and the prognostic impact of interhospital variations in the administration of adjuvant chemotherapy for Stage II-III colorectal cancer. METHOD We conducted a multicentre, retrospective study of 17 757 patients with Stage II-III colorectal cancer treated between 1997 and 2008 in 23 hospitals in Japan. Hospitals were classified as high-rate (rate > 42.8%) or low-rate (rate ≤ 42.8%), chemotherapy prescribing clinics. RESULTS The 5-year overall survival (OS) of patients with Stage II-III colorectal cancer receiving adjuvant chemotherapy was significantly higher than for those not receiving adjuvant chemotherapy (85.7% vs 79.2%, P
- Published
- 2018
- Full Text
- View/download PDF